{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:44:26Z","timestamp":1782823466642,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:00:00Z","timestamp":1605225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:00:00Z","timestamp":1605225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00592-020-01634-1","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T12:02:37Z","timestamp":1605268957000},"page":"411-417","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The utility of assessing C-peptide in patients with insulin-treated type 2 diabetes: a cross-sectional study"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9139-7159","authenticated-orcid":false,"given":"Tuccinardi","family":"Dario","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgino","family":"Riccardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieralice","family":"Silvia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Watanabe","family":"Mikiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggi","family":"Daria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palermo","family":"Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Defeudis","family":"Giuseppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fioriti","family":"Elvira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5090-636X","authenticated-orcid":false,"given":"Pozzilli","family":"Paolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfrini","family":"Silvia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,13]]},"reference":[{"key":"1634_CR1","unstructured":"World Health Organization. Health topics. Obesity. https:\/\/www.who.int\/topics\/obesity\/en\/. https:\/\/www.who.int\/topics\/obesity\/en\/. 2020"},{"key":"1634_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s40519-020-00936-1","author":"M Watanabe","year":"2020","unstructured":"Watanabe M, Risi R, De Giorgi F et al (2020) Obesity treatment within the Italian national healthcare system tertiary care centers: what can we learn? Eat Weight Disord. https:\/\/doi.org\/10.1007\/s40519-020-00936-1","journal-title":"Eat Weight Disord"},{"issue":"6","key":"1634_CR3","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.2337\/dc11-0442","volume":"34","author":"FB Hu","year":"2011","unstructured":"Hu FB (2011) Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care 34(6):1249\u20131257. https:\/\/doi.org\/10.2337\/dc11-0442","journal-title":"Diabetes Care"},{"key":"1634_CR4","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1210\/clinem\/dgaa336","volume":"105","author":"S Basciani","year":"2020","unstructured":"Basciani S, Camajani E, Contini S et al (2020) Very-low-calorie ketogenic diets with whey, vegetable or animal protein in patients with obesity: a randomized pilot study. J Clin Endocrinol Metab 105:336. https:\/\/doi.org\/10.1210\/clinem\/dgaa336","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1634_CR5","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s12020-014-0355-2","volume":"48","author":"S Basciani","year":"2015","unstructured":"Basciani S, Costantini D, Contini S et al (2015) Safety and efficacy of a multiphase dietetic protocol with meal replacements including a step with very low calorie diet. Endocrine 48(3):863\u2013870. https:\/\/doi.org\/10.1007\/s12020-014-0355-2","journal-title":"Endocrine"},{"key":"1634_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/nu12020333","author":"A Bruci","year":"2020","unstructured":"Bruci A, Tuccinardi D, Tozzi R et al (2020) Very low-calorie ketogenic diet: a safe and effective tool for weight loss in patients with obesity and mild kidney failure. Nutrients. https:\/\/doi.org\/10.3390\/nu12020333","journal-title":"Nutrients"},{"key":"1634_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/1743-7075-11-39","author":"A Soare","year":"2014","unstructured":"Soare A, Khazrai YM, Del Toro R et al (2014) The effect of the macrobiotic Ma-Pi 2 diet versus the recommended diet in the management of type 2 diabetes: the randomized controlled MADIAB trial. Nutr Metab (Lond). https:\/\/doi.org\/10.1186\/1743-7075-11-39","journal-title":"Nutr Metab (Lond)"},{"issue":"6","key":"1634_CR8","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.2337\/dc07-0048","volume":"30","author":"ARG Look","year":"2007","unstructured":"Look ARG, Pi-Sunyer X, Blackburn G et al (2007) Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 30(6):1374\u20131383. https:\/\/doi.org\/10.2337\/dc07-0048","journal-title":"Diabetes Care"},{"key":"1634_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/nu10050586","author":"M Watanabe","year":"2018","unstructured":"Watanabe M, Gangitano E, Francomano D et al (2018) Mangosteen extract shows a potent insulin sensitizing effect in obese female patients: a prospective randomized controlled pilot study. Nutrients. https:\/\/doi.org\/10.3390\/nu10050586","journal-title":"Nutrients"},{"issue":"6","key":"1634_CR10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1177\/0897190016663070","volume":"30","author":"Z Yilmaz","year":"2017","unstructured":"Yilmaz Z, Piracha F, Anderson L, Mazzola N (2017) Supplements for diabetes mellitus: a review of the literature. J Pharm Pract 30(6):631\u2013638. https:\/\/doi.org\/10.1177\/0897190016663070","journal-title":"J Pharm Pract"},{"issue":"8","key":"1634_CR11","doi-asserted-by":"publisher","first-page":"e222","DOI":"10.1038\/nutd.2016.29","volume":"6","author":"A Soare","year":"2016","unstructured":"Soare A, Del Toro R, Khazrai YM et al (2016) A 6-months follow-up study of the randomized controlled Ma\u2013Pi macrobiotic dietary intervention (MADIAB trial) in type 2 diabetes. Nutr Diabetes 6(8):e222. https:\/\/doi.org\/10.1038\/nutd.2016.29","journal-title":"Nutr Diabetes"},{"key":"1634_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13053","author":"M Watanabe","year":"2020","unstructured":"Watanabe M, Tuccinardi D, Ernesti I et al (2020) Scientific evidence underlying contraindications to the ketogenic diet: an update. Obes Rev. https:\/\/doi.org\/10.1111\/obr.13053","journal-title":"Obes Rev"},{"issue":"6","key":"1634_CR13","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1111\/dom.13655","volume":"21","author":"D Tuccinardi","year":"2019","unstructured":"Tuccinardi D, Farr OM, Upadhyay J et al (2019) Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: a six-month, randomized, placebo-controlled, double-blind clinical trial. Diabetes Obes Metab 21(6):1487\u20131492. https:\/\/doi.org\/10.1111\/dom.13655","journal-title":"Diabetes Obes Metab"},{"key":"1634_CR14","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.2337\/dc19-S009","volume":"42","author":"American Diabetes A","year":"2019","unstructured":"American Diabetes A (2019) 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care 42:S90\u2013S102. https:\/\/doi.org\/10.2337\/dc19-S009","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"1634_CR15","doi-asserted-by":"publisher","first-page":"S260","DOI":"10.2337\/dc09-S319","volume":"32","author":"RG Bretzel","year":"2009","unstructured":"Bretzel RG, Eckhard M, Landgraf W, Owens DR, Linn T (2009) Initiating insulin therapy in type 2 diabetic patients failing on oral hypoglycemic agents: basal or prandial insulin? The APOLLO trial and beyond. Diabetes Care 32(Suppl 2):S260-265. https:\/\/doi.org\/10.2337\/dc09-S319","journal-title":"Diabetes Care"},{"key":"1634_CR16","volume-title":"Centers for disease control and prevention","author":"Centers for Disease Control and Prevention. National Diabetes Statistics Report","year":"2020","unstructured":"Centers for Disease Control and Prevention. National Diabetes Statistics Report (2020) Centers for disease control and prevention. US Department of Health and Human Services, Atlanta, GA"},{"issue":"Suppl 2","key":"1634_CR17","doi-asserted-by":"publisher","first-page":"S253","DOI":"10.2337\/dc09-S318","volume":"32","author":"SG Swinnen","year":"2009","unstructured":"Swinnen SG, Hoekstra JB, DeVries JH (2009) Insulin therapy for type 2 diabetes. Diabetes Care 32(Suppl 2):S253-259. https:\/\/doi.org\/10.2337\/dc09-S318","journal-title":"Diabetes Care"},{"issue":"9","key":"1634_CR18","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/BF00404145","volume":"33","author":"M Landin-Olsson","year":"1990","unstructured":"Landin-Olsson M, Nilsson KO, Lernmark A, Sundkvist G (1990) Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus. Diabetologia 33(9):561\u2013568. https:\/\/doi.org\/10.1007\/BF00404145","journal-title":"Diabetologia"},{"key":"1634_CR19","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.2337\/dc20-S002","volume":"43","author":"American Diabetes A","year":"2020","unstructured":"American Diabetes A (2020) 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care 43:S14\u2013S31. https:\/\/doi.org\/10.2337\/dc20-S002","journal-title":"Diabetes Care"},{"issue":"9","key":"1634_CR20","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.2337\/diacare.23.9.1326","volume":"23","author":"E Sabbah","year":"2000","unstructured":"Sabbah E, Savola K, Ebeling T et al (2000) Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset type 1 diabetes. Diabetes Care 23(9):1326\u20131332. https:\/\/doi.org\/10.2337\/diacare.23.9.1326","journal-title":"Diabetes Care"},{"issue":"6","key":"1634_CR21","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/dmrr.1214","volume":"27","author":"E Di Stasio","year":"2011","unstructured":"Di Stasio E, Maggi D, Berardesca E et al (2011) Blue eyes as a risk factor for type 1 diabetes. Diabetes Metab Res Rev 27(6):609\u2013613. https:\/\/doi.org\/10.1002\/dmrr.1214","journal-title":"Diabetes Metab Res Rev"},{"issue":"11","key":"1634_CR22","doi-asserted-by":"publisher","first-page":"e009088","DOI":"10.1136\/bmjopen-2015-009088","volume":"5","author":"BM Shields","year":"2015","unstructured":"Shields BM, Peters JL, Cooper C et al (2015) Can clinical features be used to differentiate type 1 from type 2 diabetes? a systematic review of the literature. BMJ Open 5(11):e009088. https:\/\/doi.org\/10.1136\/bmjopen-2015-009088","journal-title":"BMJ Open"},{"issue":"2","key":"1634_CR23","doi-asserted-by":"publisher","first-page":"250","DOI":"10.2337\/dc15-0258","volume":"39","author":"AG Jones","year":"2016","unstructured":"Jones AG, McDonald TJ, Shields BM et al (2016) Markers of beta-cell failure predict poor glycemic response to glp-1 receptor agonist therapy in type 2 diabetes. Diabetes Care 39(2):250\u2013257. https:\/\/doi.org\/10.2337\/dc15-0258","journal-title":"Diabetes Care"},{"issue":"6","key":"1634_CR24","doi-asserted-by":"publisher","first-page":"305","DOI":"10.4158\/EP.5.6.305","volume":"5","author":"A Lee","year":"1999","unstructured":"Lee A, Morley J (1999) Classification of type 2 diabetes by clinical response to metformin-troglitazone combination and C-Peptide criteria. Endocr Pract 5(6):305\u2013313. https:\/\/doi.org\/10.4158\/EP.5.6.305","journal-title":"Endocr Pract"},{"key":"1634_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6823-12-6","author":"AG Jones","year":"2012","unstructured":"Jones AG, Besser RE, Shields BM, McDonald TJ, Hope SV, Knight BA, Hattersley AT (2012) Assessment of endogenous insulin secretion in insulin treated diabetes predicts postprandial glucose and treatment response to prandial insulin. BMC Endocr Disord. https:\/\/doi.org\/10.1186\/1472-6823-12-6","journal-title":"BMC Endocr Disord"},{"issue":"11","key":"1634_CR26","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.2337\/dc16-0619","volume":"39","author":"MG White","year":"2016","unstructured":"White MG, Shaw JA, Taylor R (2016) Type 2 diabetes: the pathologic basis of reversible beta-cell dysfunction. Diabetes Care 39(11):2080\u20132088. https:\/\/doi.org\/10.2337\/dc16-0619","journal-title":"Diabetes Care"},{"issue":"6","key":"1634_CR27","doi-asserted-by":"publisher","first-page":"451","DOI":"10.4093\/dmj.2018.0190","volume":"42","author":"S Pieralice","year":"2018","unstructured":"Pieralice S, Pozzilli P (2018) Latent autoimmune diabetes in adults: a review on clinical implications and management. Diabetes Metab J 42(6):451\u2013464. https:\/\/doi.org\/10.4093\/dmj.2018.0190","journal-title":"Diabetes Metab J"},{"issue":"8","key":"1634_CR28","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1007\/s00125-011-2167-8","volume":"54","author":"JE Foley","year":"2011","unstructured":"Foley JE, Bunck MC, Moller-Goede DL et al (2011) Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia 54(8):1985\u20131991. https:\/\/doi.org\/10.1007\/s00125-011-2167-8","journal-title":"Diabetologia"},{"issue":"2","key":"1634_CR29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.4093\/dmj.2016.40.2.99","volume":"40","author":"S Chon","year":"2016","unstructured":"Chon S, Gautier JF (2016) An update on the effect of incretin-based therapies on beta-cell function and mass. Diabetes Metab J 40(2):99\u2013114. https:\/\/doi.org\/10.4093\/dmj.2016.40.2.99","journal-title":"Diabetes Metab J"},{"issue":"3","key":"1634_CR30","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/1753-0407.12494","volume":"9","author":"H Kaneto","year":"2017","unstructured":"Kaneto H, Obata A, Kimura T et al (2017) Beneficial effects of sodium-glucose cotransporter 2 inhibitors for preservation of pancreatic beta-cell function and reduction of insulin resistance. J Diabetes 9(3):219\u2013225. https:\/\/doi.org\/10.1111\/1753-0407.12494","journal-title":"J Diabetes"},{"issue":"3","key":"1634_CR31","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s13300-017-0265-4","volume":"8","author":"E Leighton","year":"2017","unstructured":"Leighton E, Sainsbury CA, Jones GC (2017) A Practical review of C-peptide testing in diabetes. Diabetes Ther 8(3):475\u2013487. https:\/\/doi.org\/10.1007\/s13300-017-0265-4","journal-title":"Diabetes Ther"},{"issue":"1","key":"1634_CR32","doi-asserted-by":"publisher","first-page":"e3071","DOI":"10.1002\/dmrr.3071","volume":"35","author":"MT Alves","year":"2019","unstructured":"Alves MT, Ortiz MMO, Dos Reis G et al (2019) The dual effect of C-peptide on cellular activation and atherosclerosis: protective or not? Diabetes Metab Res Rev 35(1):e3071. https:\/\/doi.org\/10.1002\/dmrr.3071","journal-title":"Diabetes Metab Res Rev"},{"issue":"4","key":"1634_CR33","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1046\/j.1523-1755.2000.00335.x","volume":"58","author":"AM Covic","year":"2000","unstructured":"Covic AM, Schelling JR, Constantiner M, Iyengar SK, Sedor JR (2000) Serum C-peptide concentrations poorly phenotype type 2 diabetic end-stage renal disease patients. Kidney Int 58(4):1742\u20131750. https:\/\/doi.org\/10.1046\/j.1523-1755.2000.00335.x","journal-title":"Kidney Int"},{"issue":"1","key":"1634_CR34","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s001250050643","volume":"40","author":"SM Haffner","year":"1997","unstructured":"Haffner SM, Miettinen H, Stern MP (1997) Are risk factors for conversion to NIDDM similar in high and low risk populations? Diabetologia 40(1):62\u201366. https:\/\/doi.org\/10.1007\/s001250050643","journal-title":"Diabetologia"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-020-01634-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-020-01634-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-020-01634-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,18]],"date-time":"2021-04-18T17:06:39Z","timestamp":1618765599000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-020-01634-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,13]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1634"],"URL":"https:\/\/doi.org\/10.1007\/s00592-020-01634-1","relation":{},"ISSN":["0940-5429","1432-5233"],"issn-type":[{"value":"0940-5429","type":"print"},{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,13]]},"assertion":[{"value":"9 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interests"}},{"value":"The study has been approved by the University Campus Bio-Medico Ethics Committee # 54\/20 OSS ComEt CBM.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients signed an informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The manuscript received the consent to be published.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}